This article includes a list of references, but its sources remain unclear because it has insufficient inline citations. (July 2014) (Learn how and when to remove this template message)
Purines are biologically synthesized as nucleotides and in particular as ribotides, i.e. bases attached to ribose 5-phosphate. Both adenine and guanine are derived from the nucleotide inosine monophosphate (IMP), which is the first compound in the pathway to have a completely formed purine ring system.
Inosine monophosphate is synthesized on a pre-existing ribose-phosphate through a complex pathway (as shown in the figure on the right). The source of the carbon and nitrogen atoms of the purine ring, 5 and 4 respectively, come from multiple sources. The amino acid glycine contributes all its carbon (2) and nitrogen (1) atoms, with additional nitrogen atoms from glutamine (2) and aspartic acid (1), and additional carbon atoms from formyl groups (2), which are transferred from the coenzyme tetrahydrofolate as 10-formyltetrahydrofolate, and a carbon atom from bicarbonate (1). Formyl groups build carbon-2 and carbon-8 in the purine ring system, which are the ones acting as bridges between two nitrogen atoms.
A key regulatory step is the production of 5-phospho-α-D-ribosyl 1-pyrophosphate (PRPP) by ribose phosphate pyrophosphokinase, which is activated by inorganic phosphate and inactivated by purine ribonucleotides. It is not the committed step to purine synthesis because PRPP is also used in pyrimidine synthesis and salvage pathways.
The first committed step is the reaction of PRPP, glutamine and water to 5'-phosphoribosylamine (PRA), glutamate, and pyrophosphate - catalyzed by amidophosphoribosyltransferase, which is activated by PRPP and inhibited by AMP, GMP and IMP.
PRPP + L-Glutamine + H2O → PRA + L-Glutamate + PPi
In the second step react PRA, glycine and ATP to create GAR, ADP, and pyrophosphate - catalyzed by phosphoribosylamine—glycine ligase (GAR synthetase). Due to the chemical lability of PRA, which has a half-life of 38 seconds at PH 7.5 and 37 °C, researchers have suggested that the compound is channeled from amidophosphoribosyltransferase to GAR synthetase in vivo.
PRA + Glycine + ATP → GAR + ADP + Pi
The third is catalyzed by phosphoribosylglycinamide formyltransferase.
The fourth is catalyzed by phosphoribosylformylglycinamidine synthase.
fGAR + L-Glutamine + ATP → fGAM + L-Glutamate + ADP + Pi
The fifth is catalyzed by AIR synthetase (FGAM cyclase).
fGAM + ATP → AIR + ADP + Pi + H2O
The sixth is catalyzed by phosphoribosylaminoimidazole carboxylase.
The seventh is catalyzed by phosphoribosylaminoimidazolesuccinocarboxamide synthase.
The eight is catalyzed by adenylosuccinate lyase.
The products AICAR and fumarate move on to two different pathways. AICAR serves as the reactant for the ninth step, while fumarate is transported to the citric acid cycle which can then skip the carbon dioxide evolution steps to produce malate. The conversion of fumarate to malate is catalyzed by fumarase. In this way, fumarate connects purine synthesis to the citric acid cycle.
The ninth is catalyzed by phosphoribosylaminoimidazolecarboxamide formyltransferase.
AICAR + fTHF → FAICAR + THF
The last step is catalyzed by Inosine monophosphate synthase.
FAICAR → IMP + H2O
In eukaryotes the second, third, and fifth step are catalyzed by trifunctional purine biosynthetic protein adenosine-3, which is encoded by the GART gene.
Both ninth and tenth step are accomplished by a single protein named Bifunctional purine biosynthesis protein PURH, encoded by the ATIC gene.
- IMP dehydrogenase (IMPDH) converts IMP into XMP
- GMP synthase converts XMP into GMP
- GMP reductase converts GMP back into IMP
- adenylosuccinate synthase converts IMP to adenylosuccinate
- adenylosuccinate lyase converts adenylosuccinate into AMP
- AMP deaminase converts AMP back into IMP
Purines are metabolised by several enzymes:
- A nuclease frees the nucleotide
- A nucleotidase creates guanosine
- Purine nucleoside phosphorylase converts guanosine to guanine
- Guanase converts guanine to xanthine
- Xanthine oxidase (a form of xanthine oxidoreductase) catalyzes the oxidation of xanthine to uric acid
- A nuclease frees the nucleotide
- Purine nucleoside phosphorylase acts upon inosine to create hypoxanthine
- Xanthine oxidase catalyzes the biotransformation of hypoxanthine to xanthine
- Xanthine oxidase acts upon xanthine to create uric acid
Regulations of purine nucleotide biosynthesis
The formation of 5'-phosphoribosyalamine from glutamine and PRPP catalysed by PRPP amino transferase is the regulation point for purine synthesis.The enzyme is an allosteric enzyme, so it can be converted from IMP, GMP and AMP in high concentration binds the enzyme to exerts inhibition while PRPP is in large amount binds to the enzyme which causes activation. So IMP, GMP and AMP are inhibitors while PRPP is an activator. Between the formation of 5'-phosphoribosyl, aminoimidazole and IMP, there is no known regulation step.
Purines from turnover of cellular nucleic acids (or from food) can also be salvaged and reused in new nucleotides.
- The enzyme adenine phosphoribosyltransferase (APRT) salvages adenine.
- The enzyme hypoxanthine-guanine phosphoribosyltransferase (HGPRT) salvages guanine and hypoxanthine. (Genetic deficiency of HGPRT causes Lesch-Nyhan syndrome.)
When a defective gene causes gaps to appear in the metabolic recycling process for purines and pyrimidines, these chemicals are not metabolised properly, and adults or children can suffer from any one of twenty-eight hereditary disorders, possibly some more as yet unknown. Symptoms can include gout, anaemia, epilepsy, delayed development, deafness, compulsive self-biting, kidney failure or stones, or loss of immunity.
Purine metabolism can have imbalances that can arise from harmful nucleotide triphosphosphates incorporating into DNA and RNA which further lead to genetic disturbances and mutations, and as a result, give rise to several types of diseases. Some of the diseases are:
1. Severe Immunodeficiency by loss of adenosine deaminase.
2. Hyperuricemia and Lesch-Nyhan syndrome by the loss of hypoxanthine-guanine phosphoribosyltransferase.
3. Different types of cancer by an increase in the activities of enzymes like IMP dehydrogenase.
Modulation of purine metabolism has pharmacotherapeutic value.
Purine synthesis inhibitors inhibit the proliferation of cells, especially leukocytes. These inhibitors include azathioprine, an immunosuppressant used in organ transplantation, autoimmune disease such as rheumatoid arthritis or inflammatory bowel disease such as Crohn's disease and ulcerative colitis.
Mycophenolate mofetil is an immunosuppressant drug used to prevent rejection in organ transplantation; it inhibits purine synthesis by blocking inositol monophosphate dehydrogenase. Also Methotrexate indirectly inhibits purine synthesis by blocking the metabolism of folic acid (it is an inhibitor of the dihydrofolate reductase).
Allopurinol is a drug that inhibits the enzyme xanthine oxidoreductase and, thus, lowers the level of uric acid in the body. This may be useful in the treatment of gout, which is a disease caused by excess uric acid, forming crystals in joints.
- Antle VD, Liu D, McKellar BR, Caperelli CA, Hua M, Vince R (April 1996). "Substrate specificity of glycinamide ribonucleotide synthetase from chicken liver". The Journal of Biological Chemistry. 271 (14): 8192–5. doi:10.1074/jbc.271.14.8192. PMID 8626510.
- Garrett RH, Grisham CM (2016-02-11). Biochemistry (Sixth ed.). Boston, MA. pp. 666 & 934. ISBN 9781305577206. OCLC 914290655.
- Ansari MY, Equbal A, Dikhit MR, Mansuri R, Rana S, Ali V, et al. (February 2016). "Establishment of correlation between in-silico and in-vitro test analysis against Leishmania HGPRT to inhibitors". International Journal of Biological Macromolecules. 83: 78–96. doi:10.1016/j.ijbiomac.2015.11.051. PMID 26616453.
- Pang B, McFaline JL, Burgis NE, Dong M, Taghizadeh K, Sullivan MR, et al. (February 2012). "Defects in purine nucleotide metabolism lead to substantial incorporation of xanthine and hypoxanthine into DNA and RNA". Proceedings of the National Academy of Sciences of the United States of America. 109 (7): 2319–24. Bibcode:2012PNAS..109.2319P. doi:10.1073/pnas.1118455109. JSTOR 41477470. PMC 3289290. PMID 22308425.